These data support a key role for KDM5D in modulating CHK1i sensitivity through a novel p38/COX-2 prosurvival pathway in PC cells, with potential predictive value for patients with CRPC receiving these anticancer agents. This evidence concerns the gene PTGS2 and pachyonychia congenita.